Lumavita AG, the Swiss biopharmaceutical company specializing in novel anti-infectives for women's health, announced its first product approval. Following notice of preliminary approval issued in March 2009, the Swiss regulatory authority has granted final marketing authorisation to Lumavita's proprietary prescription medication, pentamycin, for the treatment of all types of infectious vaginitis.
The details can be read here.
No comments:
Post a Comment